

Summary Report on Financial Results for the Third Quarter of the Year Ending March 31<sup>st</sup>, 2025  
(Japan GAAP)

January 31<sup>st</sup>, 2025  
Stock Listing: TSE-Standard Market

Company name: Fukuda Denshi Co., Ltd.  
Code No.: 6960 (<https://www.fukuda.co.jp>)  
Representative: Daijiro Shirai, President & COO  
Inquiries: Haruhiko Honbu, Senior Manager of Accounting & Finance Department  
Tel: +81-3-5684-1558 (main)  
Scheduled date for commencement of dividend payment: -  
Supplementary material development: None  
Financial results meeting: None

(Amounts less than one million yen are rounded down)

(The number with parenthesis shows negative figure)

1. Consolidated financial results for the Third quarter of the year ending March 31<sup>st</sup>, 2025 (April 1<sup>st</sup>, 2024 through December 31<sup>st</sup>, 2024)

(1) Consolidated operating results (cumulative)

(% represents increases or decreases from the previous year)

	Net sales		Operating Profit		Ordinary Profit		Profit attributable to owners of parent	
	million yen	%	million yen	%	million yen	%	million yen	%
Third quarter of the year ending March 31 <sup>st</sup> , 2025	99,395	0.1	17,392	(9.8)	17,990	(8.2)	12,374	(9.3)
Third quarter of the year ended March 31 <sup>st</sup> , 2024	99,258	6.2	19,286	20.0	19,603	16.9	13,636	17.5

(Note) Comprehensive income

Third quarter of the year ending March 31<sup>st</sup>, 2025: 11,365 million yen / (27.5) %

Third quarter of the year ended March 31<sup>st</sup>, 2024: 15,666 million yen / 31.1 %

	Earnings per share	Diluted earnings per share
	yen	yen
Third quarter of the year ending March 31 <sup>st</sup> , 2025	429.25	—
Third quarter of the year ended March 31 <sup>st</sup> , 2024	450.77	—

(2) Consolidated financial situation

	Total assets	Net assets	Shareholders' equity ratio	Net assets per share
	million yen	million yen	%	yen
Third quarter of the year ending March 31 <sup>st</sup> , 2025	209,429	174,856	83.5	6,065.35
Year ended March 31 <sup>st</sup> , 2024	209,064	169,008	80.8	5,863.22

(Reference) Shareholders' equity:

Third quarter of the year ending March 31<sup>st</sup>, 2025: 174,856 million yen

Fiscal year ended March 31<sup>st</sup>, 2024: 169,008 million yen

## 2. Dividends

	Annual Dividends per share				
	End of the first quarter	End of the second quarter	End of the third quarter	End of the term	Annual
	yen	yen	yen	yen	yen
Year ended March 31 <sup>st</sup> , 2024	—	80.00	—	105.00	185.00
Year ending March 31 <sup>st</sup> , 2025	—	85.00	—		
Year ending March 31 <sup>st</sup> , 2025 (forecast)				85.00	170.00

(Note 1) Revisions to recent dividend forecast: None

(Note 2)

The detail of second quarter dividend of Year ended March 31<sup>st</sup>, 2024; ordinary dividend 60.00 yen, extra dividend 20.00 yen

The detail of year-end dividend of Year ended March 31<sup>st</sup>, 2024; ordinary dividend 60.00 yen, extra dividend 45.00 yen

The detail of second quarter dividend of Year ending March 31<sup>st</sup>, 2025; ordinary dividend 60.00 yen, extra dividend 25.00 yen

The detail of year-end dividend of Year ending March 31<sup>st</sup>, 2025 (forecast); ordinary dividend 60.00 yen, extra dividend 25.00 yen

## 3. Forecast of consolidated financial results for fiscal year ending March 31<sup>st</sup>, 2025 (April 1<sup>st</sup>, 2024 through March 31<sup>st</sup>, 2025)

(% represents increase or decrease from the previous year)

	Net sales		Operating Profit		Ordinary Profit		Profit attributable to owners of parent		Earnings per share
	million yen	%	million yen	%	million yen	%	million yen	%	yen
Full-year	135,000	(3.8)	23,000	(13.2)	23,000	(14.8)	16,500	(11.7)	572.37

(Note) Revisions to recent business forecast: None

### \*Notes

(1) Significant changes in the scope of consolidation during the period: None

(2) Application of special accounting methods for the preparation of the consolidated quarterly financial statements: None

(3) Changes in accounting policies, accounting projections and restatement

(i) Changes in accounting policies associated with revision of accounting standards: Yes

(ii) Changes other than (i) above: None

(iii) Changes in accounting projections: None

(iv) Restatement: None

(4) Number of outstanding shares (common shares)

(i) Number of outstanding shares at the end of the period (including treasury shares)

Third quarter of the year ending March 31<sup>st</sup>, 2025: 37,747,300 shares

Year ended March 31<sup>st</sup>, 2024: 37,747,300 shares

(ii) Number of shares of treasury shares at the end of the period:

Third quarter of the year ending March 31<sup>st</sup>, 2025: 8,918,565 shares

Year ended March 31<sup>st</sup>, 2024: 8,922,061 shares

(iii) Average number of shares during the period (accumulated consolidated quarter)

Third quarter of the year ending March 31<sup>st</sup>, 2025: 28,827,402 shares

Third quarter of the year ended March 31<sup>st</sup>, 2024: 30,251,454 shares

\* Review of the attached consolidated quarterly financial statements by certified public accountants or an audit firm: None

\* Explanation about the appropriate use of the forecasts of financial results, and other noteworthy matters

The projections and other statements with respect to the future included in this material are based on currently available information and certain assumptions that are judged reasonable by Fukuda Denshi (hereinafter mentioned as “the Group”). Please be advised that the Group does not guarantee in any way the achievement of the projections and other goals in this material and that cases may occur where the actual results and other situations differ materially from the projections due to various factors. With respect to the preconditions for the forecast of financial results, please refer to “(3) Explanation about consolidated earnings forecast” under the “1. Operating results” section on page 5.

## Contents of the Attached Materials

1. Operating results -----	P.05
(1) Overview of operating results -----	P.05
(2) Overview of financial situation -----	P.05
(3) Explanation about consolidated earnings forecast -----	P.05
2. Consolidated quarterly financial statements and Notes -----	P.06
(1) Consolidated quarterly balance sheets -----	P.06
(2) Consolidated quarterly income statements and consolidated quarterly comprehensive income statements	P.08
Consolidated quarterly income statements	
Third quarter of the consolidated term -----	P.08
Consolidated quarterly comprehensive income statements	
Third quarter of the consolidated term -----	P.09
(3) Notes to consolidated quarterly financial statement -----	P.09
(Notes regarding changes in Accounting Policy) -----	P.09
(Notes regarding segment information, etc.) -----	P.10
(Notes when there is a significant fluctuation in the amount of shareholders' equity) -----	P.11
(Notes regarding the premise for going concern) -----	P.11
(Notes regarding consolidated quarterly statements of cash flows) -----	P.11

## 1. Operating results

### (1) Overview of operating results

Although the Japanese economy has been gradually recovering during the consolidated cumulative third quarter of this fiscal year (April 1<sup>st</sup>, 2024 through March 31<sup>st</sup>, 2025), there is still uncertainty about the future due to factors such as soaring resource prices influenced by the international situation and the monetary policy shift in Europe and America.

In the medical industry, it is now necessary to continue building systems to prepare for future infectious disease while promoting of medical DX for the digitalization of the medical field, and to establish an efficient framework to provide healthcare services that aligns with regional medical plans by enhancing the differentiation and functionality of medical institutions and promoting regional healthcare networks.

In such an environment, the Group posted consolidated “Net sales” of 99,395 million yen (up 0.1% year-on-year basis), “Operating profit” of 17,392 million yen (down 9.8% year-on-year basis), “Ordinary profit” of 17,990 million yen (down 8.2% year-on-year basis), and “Profit attributable to owners of parent” of 12,374 million yen (down 9.3% year-on-year basis) in the third quarter.

#### A. Physiological diagnostic equipment segment

While the sales of electrocardiographs increased, the sales of ultrasound diagnostic systems and vascular screening systems decreased.

As a result, consolidated “Net sales” were 18,955 million yen (down 2.9% year-on-year basis).

#### B. Patient monitoring equipment segment

Consolidated “Net sales” of patient monitoring equipment were 6,749 million yen (up 12.7% year-on-year basis).

#### C. Medical treatment equipment segment

The business of renting medical equipment for home treatment and the sales of AEDs, etc. increased. As a result, consolidated “Net sales” were 45,820 million yen (up 4.0% year-on-year basis).

#### D. Consumables and other products segment

Consumables and other products segment includes the sales of recording paper, disposable electrodes, and consumables used for devices handled in the above segments, as well as maintenance and repair services.

Consolidated “Net sales” for this segment were 27,871 million yen (down 6.1% year-on-year basis).

### (2) Explanation about consolidated financial situation

“Total assets” increased 364 million yen from the end of previous fiscal year to reach 209,429 million yen. The main factors of this are the increase of 5,753 million yen in “Cash and deposits” and 1,958 million yen in “Tools, furniture and fixtures” despite the decrease of 6,506 million yen in “Notes and accounts receivable - trade”.

“Total liabilities” decreased 5,483 million yen from the end of the previous fiscal year to reach 34,572 million yen. The main factor is the decrease of 2,594 million yen in “Income taxes payable” and 2,210 million yen in “Provision for bonuses”.

“Net assets” increased 5,847 million yen from the end of the previous fiscal year to reach 174,856 million yen. The main factor is the increase of 6,849 million yen in “Retained earnings” despite the decrease of 1,035 million yen in “Valuation difference on available-for-sale securities”.

### (3) Explanation about consolidated earnings forecast

Due to the steady sales performance for the cumulative period of the third quarter, there is no change at this moment in the forecast of the financial results for the full fiscal year which we announced on May 15<sup>th</sup>, 2024.

The forecasted financial results described in this material are based on information available at the time of announcement. Actual results may differ from the results projected and presented hereby for a variety of reasons.

## 2. Consolidated quarterly financial statements and Notes

### (1) Consolidated quarterly balance sheets

(Million yen)

	As of March 31 <sup>st</sup> , 2024	As of December 31 <sup>st</sup> , 2024
<b>Assets</b>		
Current assets		
Cash and deposits	60,222	65,975
Notes and accounts receivable - trade	36,770	30,263
Electronically recorded monetary claims - operating	4,447	4,264
Merchandise and finished goods	11,362	11,386
Work in process	240	314
Raw materials and supplies	4,054	4,049
Other	2,076	1,871
Allowance for doubtful accounts	(38)	(32)
Total current assets	119,136	118,093
Non-current assets		
Property, plant and equipment	51,575	54,587
Intangible assets	1,862	1,705
Investments and other assets		
Investment securities	15,496	14,187
Other	21,000	20,863
Allowance for doubtful accounts	(6)	(7)
Total investments and other assets	36,489	35,042
Total non-current assets	89,928	91,335
Total assets	209,064	209,429
<b>Liabilities</b>		
Current liabilities		
Notes and accounts payable - trade	11,611	12,681
Electronically recorded obligations - operating	4,753	3,740
Short-term borrowings	1,750	1,800
Income taxes payable	3,856	1,262
Provision for product warranties	149	179
Provision for bonuses	3,816	1,606
Other provisions	547	410
Other	7,947	7,435
Total current liabilities	34,431	29,115
Non-current liabilities		
Retirement benefit liability	2,031	2,047
Other provisions	810	757
Other	2,782	2,652
Total non-current liabilities	5,624	5,457
Total liabilities	40,056	34,572

(Million yen)

	As of March 31 <sup>st</sup> , 2024	As of December 31 <sup>st</sup> , 2024
Net assets		
Shareholders' equity		
Share capital	4,621	4,621
Capital surplus	17,506	17,506
Retained earnings	167,359	174,208
Treasury shares	(27,266)	(27,258)
Total shareholders' equity	162,220	169,077
Accumulated other comprehensive income		
Valuation difference on available-for-sale securities	5,594	4,559
Foreign currency translation adjustment	578	700
Remeasurements of defined benefit plans	613	519
Total accumulated other comprehensive income	6,787	5,778
Total net assets	169,008	174,856
Total liabilities and net assets	209,064	209,429

(2) Consolidated quarterly income statements and consolidated quarterly comprehensive income statements

Consolidated quarterly income statements  
(Third quarter of the consolidated term)

	(Million yen)	
	Third quarter of the previous consolidated term (from April 1 <sup>st</sup> , 2023 to December 31 <sup>st</sup> , 2023)	Third quarter of the consolidated term (from April 1 <sup>st</sup> , 2024 to December 31 <sup>st</sup> , 2024)
Net sales	99,258	99,395
Cost of sales	45,332	47,129
Gross profit	53,926	52,266
Selling, general and administrative expenses	34,639	34,874
Operating profit	19,286	17,392
Non-operating income		
Interest income	70	73
Dividend income	168	206
Gain on investments in investment partnership	1	78
Insurance claim income	13	158
Other	134	216
Total non-operating income	387	732
Non-operating expenses		
Interest expenses	25	30
Foreign exchange losses	27	85
Other	18	18
Total non-operating expenses	70	134
Ordinary profit	19,603	17,990
Extraordinary income		
Gain on sales of non-current assets	5	120
Surrender value of insurance policies	197	103
Total extraordinary income	202	224
Extraordinary losses		
Loss on sales of non-current assets	5	34
Impairment losses	5	12
Loss on valuation of investment securities	26	-
Office relocation expenses	8	-
Total extraordinary losses	46	46
Profit before income taxes	19,759	18,168
Income taxes - current	5,671	5,077
Income taxes - deferred	451	716
Total income taxes	6,122	5,793
Profit	13,636	12,374
Profit attributable to owners of parent	13,636	12,374



Consolidated quarterly comprehensive income statements  
(Third quarter of the consolidated term)

	(Million yen)	
	Third quarter of the previous consolidated term (from April 1 <sup>st</sup> , 2023 to December 31 <sup>st</sup> , 2023)	Third quarter of the consolidated term (from April 1 <sup>st</sup> , 2024 to December 31 <sup>st</sup> , 2024)
Profit	13,636	12,374
Other comprehensive income		
Valuation difference on available-for-sale securities	1,861	(1,035)
Foreign currency translation adjustment	197	121
Remeasurements of defined benefit plans, net of tax	(29)	(94)
Total other comprehensive income	2,029	(1,009)
Comprehensive income	15,666	11,365
Comprehensive income attributable to		
Comprehensive income attributable to owners of parent	15,666	11,365

(3) Notes to consolidated quarterly financial statement

(Notes regarding changes in Accounting Policies)

Application of Accounting Standard for Current Income Taxes:

The “Accounting Standard for Current Income Taxes” (ASBJ Statement No. 27, October 28<sup>th</sup>, 2022; hereinafter, “Revised Accounting Standard 2022”), etc. has been applied from the beginning of the first quarter of the current consolidated fiscal year.

Revisions concerning the categories in which current income taxes should be recorded (taxes on other comprehensive income) are subject to the transitional treatment set forth in the proviso of paragraph 20-3 of the Revised Accounting Standard 2022 and the transitional treatment set forth in the proviso of paragraph 65-2 (2) of the Guidance on Accounting Standard for Tax Effect Accounting (ASBJ Guidance No. 28, October 28<sup>th</sup>, 2022; hereinafter, “Revised Guidance 2022”). The change in accounting policies had no impact on the Group’s consolidated financial statements.

With regard to revisions related to changes in the accounting treatment for consolidated financial statements when gains/losses on sale of shares, etc. in subsidiaries resulting from transactions between consolidated subsidiaries are deferred for tax purposes, the Group has applied the Revised Guidance 2022 from the beginning of the first quarter of the current consolidated fiscal year. This change in accounting policies was applied retrospectively to the consolidated financial statements for the first quarter of the previous fiscal year and the entire previous fiscal year. The change in the accounting policies had no impact on the consolidated financial statements for the third quarter of the previous fiscal year or the entire previous fiscal year.

(Notes regarding segment information, etc.)

(i) Previous fiscal year (from April 1<sup>st</sup>, 2023 to December 31<sup>st</sup>, 2023)

1. Net Sales and Profit (Loss) by Reportable Segment and Breakdown of Revenue

(Million yen)

	Reporting Segments				Total	Adjustments	Consolidated quarterly income statements *1
	Physiological diagnostic equipment	Patient monitoring equipment	Medical treatment equipment	Consumables and other products			
Net sales							
Domestic Sales	18,984	5,326	44,068	28,719	97,099	-	97,099
Overseas Sales	530	662	-	966	2,159	-	2,159
Revenue from Contracts with Customers	19,515	5,989	44,068	29,685	99,258	-	99,258
Sales to external customers	19,515	5,989	44,068	29,685	99,258	-	99,258
Internal sales or transfers	-	-	-	-	-	-	-
Total	19,515	5,989	44,068	29,685	99,258	-	99,258
Segment Profit	3,344	1,113	9,424	5,404	19,286	-	19,286

\*1. Segment profit equals to “Operating profit” of consolidated quarterly income statements.

2. Information on impairment loss for noncurrent assets and goodwill by reportable segment:

Omitted for lack of significance.

(ii) Current fiscal year (from April 1<sup>st</sup>, 2024 to December 31<sup>st</sup>, 2024)

1. Net Sales and Profit (Loss) by Reportable Segment and Breakdown of Revenue

(Million yen)

	Reporting Segments				Total	Adjustments	Consolidated quarterly income statements *1
	Physiological diagnostic equipment	Patient monitoring equipment	Medical treatment equipment	Consumables and other products			
Net sales							
Domestic Sales	18,652	5,779	45,820	26,772	97,024	-	97,024
Overseas Sales	302	969	-	1,098	2,371	-	2,371
Revenue from Contracts with Customers	18,955	6,749	45,820	27,871	99,395	-	99,395
Sales to external customers	18,955	6,749	45,820	27,871	99,395	-	99,395
Internal sales or transfers	-	-	-	-	-	-	-
Total	18,955	6,749	45,820	27,871	99,395	-	99,395
Segment Profit	3,033	1,123	8,862	4,371	17,392	-	17,392

\*1. Segment profit equals to “Operating profit” of consolidated quarterly income statements.

2. Information on impairment loss for noncurrent assets and goodwill by reportable segment:

Omitted for lack of significance.

(Notes when there is a significant fluctuation in the amount of shareholders' equity)

Not applicable.

(Notes regarding the premise for going concern)

Not applicable.

(Notes regarding consolidated quarterly statements of cash flows)

The Group has not prepared the consolidated quarterly statements of cash flows for the third quarter of the current consolidated fiscal year. Depreciation, including amortization related to intangible assets excluding goodwill, for the third quarter is as follows:

	(Million yen)	
	Third quarter of the previous consolidated term (from April 1 <sup>st</sup> , 2023 to December 31 <sup>st</sup> , 2023)	Third quarter of the consolidated term (from April 1 <sup>st</sup> , 2024 to December 31 <sup>st</sup> , 2024)
Depreciation	7,090	7,791

\* This English translation is for reference purposes only. The original Japanese version will prevail as the official authoritative version.

\* The original disclosure in Japanese was released on January 31<sup>st</sup>, 2025 at 15:30 (GMT+9)